Germantown, Maryland-based Senseonics' Eversense continuous glucose monitor, which promises to be less invasive and longer lasting than traditional CGMs, still isn’t FDA cleared or CE-marked. But the company, which filed for an IPO last month, is pushing ahead on a partnership to maximize the user experience of its device, and to establish a pipeline for sending its data to users’ healthcare providers.
Senseonics recently announced a partnership with diasend, a Swedish diabetes data management company. Diasend integrates data from a number of different glucometers, CGMs, and insulin pumps and pulls that data into a consumer app for Apple and Android. It also uses it to prepare reports that can be sent to clinicians. The app integrates with activity trackers so users can gauge their blood sugar against activity.
“We believe that turning data from CGM and or pump devices into actionable data is extremely important to users,” Dr. Tim Goodnow, CEO and President of Senseonics, said in a statement. “Our aim with the Eversense CGM system is to help people with diabetes spend less time managing their devices and more time managing their diabetes. … Senseonics is extremely pleased to be working with a partner as valuable as diasend, a company that is already well-known and trusted by the diabetes community, to allow users to have access to additional historical data and a more comprehensive data management solution.”
Senseonics’ singular offering is a pill-sized sensor that is entirely implanted in the user’s upper arm so that it can continuously monitor their glucose levels. The device is meant to last at least 90 days before it needs to be replaced — in contrast to the five to seven days that current not-quite-so-invasive CGMs last. The sensor sends data to a transmitter that a users wears on their upper arm. When on the user’s upper arm, the transmitter can take readings from the implanted sensor and send them to a companion smartphone app. The transmitter can also connect to the user’s computer via USB to upload glucose history.
Diasend partnered with Dexcom last fall to integrate with Dexcom’s G5 Mobile CGM. They work with a wide range of devices from Dexcom, Abbott, Roche, Bayer, Sanofi, and more. However, they currently don’t integrate with any Medtronic devices.
While Sensionics and diasend are targeting Europe as an initial market for their integrated offering, it’s worth noting that diasend’s platform already has FDA clearance. So when, or if, Senseonics gets its device cleared, it will be that much easier to bring the integrated platform to the US.
